AMSBIO has further expanded its product range to help in the fight against COVID-19 with the introduction of a new range of aptamers targeting SARS-CoV-2 proteins to aid development of new kits and assays.
Aptamers are small single-stranded RNA or DNA oligonucleotides that fold in a three-dimensional conformation allowing them to bind specifically to a target. This target can be an organic molecule, free or carried in cells or tissues, or inorganic components, such as metal ions. Aptamers have generated significant interest as promising tools, that compete with monoclonal antibodies, for detection and inhibition of specific markers of human diseases because they offer high specificity for their target, no to low immunogenicity and easy in vitro selection.
To better understand the genetic architecture of host proteins interacting with SARS-CoV-2 or mediating host response to COVID-19 - using an aptamer-based technique can help to identify new or repurpose existing drugs targeting those proteins.
As aptamers bind targets with high selectivity and specificity, they are an ideal tool to help develop new approaches to early-stage diagnostic assay and adequate therapy. With AMSBIO aptamers targeting SARS-CoV-2 S1 protein, S2 protein, RBD protein or nucleocapsid protein, they can be used in wide range of detection methods and for development of COVID-19 diagnostic assays.
For further information on the new range of aptamers targeting SARS-CoV-2 proteins please visit https://www.amsbio.com/aptamers-for-infectious-diseases/ or contact AMSBIO on+44-1235-828200 / +1-617-945-5033 / firstname.lastname@example.org.
Dr Bill Bradbury email@example.com